Summary: Yttrium-90 IsoPet is a water-based hydrogel designed to deliver radioactive microspheres directly into tumour tissues. Once administered, it polymerises at body temperature, entrapping yttrium-90 microspheres in a lattice that enables targeted radiotherapy. Originally called RadioGel, the product is now marketed under the name IsoPet for veterinary applications in the United States and the European Union. It has shown promise in treating various solid tumours, such as inoperable liver cancer, brain tumours, head and neck tumours, kidney tumours, pancreatic cancer, and prostate cancer. While the veterinary formulation is widely available, the human version—RadioGel—remains under investigation. This article explores the history, composition, mechanism of action, veterinary uses, safety considerations, and future prospects for human treatment.
Keywords: Yttrium-90; IsoPet; Brachytherapy; Nuclear medicine; Veterinary oncology; RadioGel.
Introduction to Injectable Brachytherapy
Cancer treatment has evolved considerably over the last few decades, embracing cutting-edge technology to offer targeted therapies with fewer side effects. One of the most remarkable breakthroughs in radiotherapy is the use of injectable brachytherapy agents that can be placed directly into tumour tissue. Brachytherapy, in its traditional form, often involves the implantation of radioactive seeds or wires. However, a newer modality employs liquid or gel carriers to deliver radioactive isotopes directly to the site of malignancy. Among these innovative formulations is Yttrium-90 IsoPet, a hydrogel liquid comprised of a biodegradable polymer. This product is designed to deliver yttrium-90 (a beta-emitting radionuclide) microspheres precisely within tumours, minimising radiation exposure to surrounding healthy tissue.
Initially developed under the name RadioGel, Yttrium-90 IsoPet holds substantial promise for both veterinary and human oncology. In 2019, it gained approval in the United States and European Union for veterinary use, thereby providing novel treatment options for animals suffering from various forms of cancer. The approach takes advantage of the principle of brachytherapy, which is localised radiation, achieving tumouricidal doses while reducing systemic toxicity. By merging biodegradable polymers and targeted radiotherapy, Yttrium-90 IsoPet heralds a new era in cancer management.
History and Development
The concept of using yttrium-90 in oncological treatments is not new. Yttrium-90 has been utilised for radioimmunotherapy and radionuclide synovectomy for several years. It is favoured partly due to its relatively short half-life of around 64 hours and high-energy beta emissions, which can destroy cancer cells effectively. The developers of Yttrium-90 IsoPet recognised these characteristics and sought to harness them by embedding the isotope in a hydrogel designed to be injectable and to solidify in situ.
Originally known as RadioGel, the prototype was conceived as a direct intratumoural injection to concentrate radioactivity exactly where it is required. During preclinical and early laboratory testing, researchers discovered that combining a water-based biodegradable polymer with yttrium-90 microspheres provided excellent stability and uniform distribution once delivered into the tissue. Over time, technical refinements in polymer chemistry and manufacturing processes improved safety and efficacy, paving the way for its eventual licensing for veterinary nuclear medicine applications under the brand name IsoPet.
In the early phases of its development, RadioGel predominantly targeted prostate cancer. Yet, as research progressed, clinicians began to realise that this technique could be extended to other tumours known to be difficult to manage with standard treatments. By the time the product was launched for veterinary use, the scope had widened significantly to include cancers of the brain, head and neck, liver, kidneys, and pancreas. The product’s versatility stems from its primary mechanism of delivering high, localised radiation doses without extensive damage to nearby healthy tissue.
Composition and Key Properties
Yttrium-90 IsoPet comprises a hydrogel solution made of a water-based biodegradable polymer. Embedded within this polymer are microspheres containing the radioactive isotope yttrium-90, which emits beta particles (β–). When injected, the hydrogel remains fluid at room temperature, allowing it to be administered through thin needles or catheters. Once exposed to body temperature, the solution polymerises or gels, creating a lattice structure that traps the yttrium-90 microspheres in place.
This in situ polymerisation is crucial for clinical success. The microspheres must remain localised to the tumour area to maximise radiation exposure precisely where it is needed while limiting the spread to healthy tissues. The hydrogel’s biodegradable nature ensures that the material eventually breaks down within the body, leaving behind minimal residue. The combination of injection-based administration and subsequent lattice formation simplifies the clinical procedure, requiring fewer invasive surgical approaches than some other brachytherapy methods.
Notably, the half-life of yttrium-90 means that the majority of radioactivity dissipates over a matter of days. This short half-life is advantageous for patient safety, as it reduces the potential for long-term radioactivity within the body. It also shortens the duration of radiation precautions compared to isotopes that have longer half-lives.
Brachytherapy Mechanism of Action
Brachytherapy is predicated on placing a radioactive source within or very close to the tumour, thus delivering radiation over a short distance. This setup minimises radiation exposure to healthy tissues and maximises the dose received by tumour cells, exploiting their relative radiosensitivity. In the case of Yttrium-90 IsoPet, the beta radiation generated by yttrium-90 penetrates a limited distance, typically a few millimetres. This characteristic spares distant tissues and organs from unnecessary radiation.
The process of destroying cancer cells involves damaging their DNA beyond repair, leading to cell death. Beta emissions are particularly efficient at causing this kind of damage in the targeted region. Because the gel physically confines the radioactive microspheres, the radiation is focused directly on the cancerous cells. After injecting the product, clinicians often use imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), or nuclear medicine scans to confirm accurate placement and distribution within the tumour.
An additional benefit of Yttrium-90 IsoPet lies in the option to customise its application. Depending on the size, shape, and type of tumour, a clinician can adjust the volume and location of injections to optimise coverage. This flexibility allows for a tailored approach, accommodating a wide variety of clinical scenarios. For instance, inaccessible superficial tumours can be injected transdermally. For larger or deeper tumours, it may be administered through direct injection using image guidance or intraoperatively to ensure it reaches the correct target site.
Veterinary Nuclear Medicine Applications
The availability of Yttrium-90 IsoPet in veterinary medicine since 2019 has revolutionised the approach to treating various animal cancers. Veterinary oncologists now have an option particularly useful for solid tumours that are considered inoperable or risky to remove via conventional surgery. This includes liver tumours, which are notoriously difficult to treat because of the organ’s essential functions and complex vasculature. Similarly, brain tumours, head and neck tumours, kidney tumours, and pancreatic cancers can be challenging, as standard surgical resection carries significant risks and post-operative complications.
Prostate cancer, once the initial clinical target for RadioGel, remains an indication of interest for the product in animals. The beta radiation from yttrium-90 can reach the malignant tissue without excessively affecting sensitive tissues adjacent to the prostate gland. Animals that might have few treatment options otherwise can benefit from this localised, high-dose radiotherapy that is administered within the confines of a short procedure.
Clinical feedback from veterinary oncologists suggests that many animals tolerate the injection well, with relatively minor acute side effects such as local swelling or discomfort at the injection site. Since the hydrogel and microspheres are biodegradable and remain primarily in the tumour, the impact of systemic radiation is minimised. Many veterinarians have reported improved tumour control and, in some instances, substantial reduction in tumour size. This can significantly extend the quality and duration of life for animals that would have otherwise faced poor prognoses.
Future Prospects for Human Medicine
The success of Yttrium-90 IsoPet in veterinary oncology has naturally piqued the interest of researchers and clinicians in human medicine. The human formulation, which will be marketed as Yttrium-90 RadioGel, is not yet widely available but shows potential for treating malignancies that either do not respond well to conventional therapies or are deemed inoperable. Tumours in the liver, brain, head and neck, pancreas, kidney, and prostate pose significant challenges for surgeons, as resection is not always feasible. The ability of Yttrium-90 RadioGel to deliver a high dose of radiation to these sites could represent a game-changing shift in treatment protocols.
An important advantage of Yttrium-90 is its emission of beta particles, which do not travel far in tissue. Consequently, high doses can be administered directly to tumours without excessively harming healthy tissue. Many conventional external beam radiotherapy methods require multiple treatment sessions, partly to spare normal cells by fractionating the dose. With an injectable formulation that remains localised, clinicians may be able to achieve equivalent or better tumour control in fewer sessions.
Furthermore, as interest in personalised medicine grows, localised radiotherapy strategies fit neatly into the broader trend of tailoring treatments to individual patient needs. By carefully mapping out tumour boundaries via imaging, specialists could plan injections that conform to the exact tumour geometry. This precision may open doors to treating previously considered untreatable tumours or that had only limited therapeutic options.
Safety Considerations and Regulatory Status
Injectable radioactive materials inevitably raise safety questions for both the patient and the medical team. Yttrium-90 IsoPet addresses many of these concerns through its short half-life and in situ polymerisation. The bulk of radiation is delivered within the tumour, and within a few days, the radioactivity significantly diminishes. Radiation safety guidelines still must be followed, including secure handling, dosimetry calculations, and possibly temporary isolation to protect caregivers, depending on the dose.
Yttrium-90 IsoPet obtained clearance in 2019 within the United States and the European Union for veterinary use. The established safety protocols and clinical outcomes have furthered interest in transferring this product for human applications. Regulatory authorities such as the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) will require rigorous clinical trials to establish efficacy, dosage parameters, and long-term safety before Yttrium-90 RadioGel enters widespread clinical practice.
Early reports from preclinical studies suggest that complications are typically related to the injection technique rather than the material itself. Accidental leakage or misplacement of the hydrogel can lead to local tissue damage or inadequate tumour coverage. Therefore, detailed imaging guidance and training will be integral to the safe administration of Yttrium-90 RadioGel. Once placed correctly, the product’s biodegradable nature and localisation properties minimise radiation exposure outside the targeted area.
Conclusion
Yttrium-90 IsoPet represents a significant advancement in brachytherapy, offering hope for tumours that cannot be managed effectively through surgery or conventional external beam radiotherapy. Its core advantage lies in the hydrogel’s capacity to deliver a targeted dose of beta-emitting microspheres directly to the malignancy, maximising therapeutic impact whilst preserving healthy tissues. The successful track record in veterinary oncology, where IsoPet is already approved, underscores the potential benefits that might be translated to human patients once regulatory approvals are secured. The future introduction of Yttrium-90 RadioGel for human use could greatly enhance personalised cancer treatment, particularly for difficult-to-treat tumours.
As research continues, it is likely that improvements in imaging, delivery techniques, and polymer chemistry will further refine the product. These refinements may widen its scope of application and streamline its use in practice. Yttrium-90 IsoPet serves as a testament to the power of targeted radiation therapy delivered via a polymer-based carrier system, reminding us that innovative formulations can reshape our therapeutic arsenal against cancer. By harnessing the precise localisation afforded by injectable brachytherapy, clinicians can offer more treatment options and better outcomes for patients—both animal and, soon, human.
You are here: home »